Market assessment of tuberculosis diagnostics in China in 2012
DESIGN: Test volumes and unit costs were assessed for tuberculin skin tests, interferon-gamma release assays (IGRAs), smear microscopy, serology, cultures, speciation tests, nucleic-acid amplification tests (NAATs), drug susceptibility tests and adenosine-deaminase tests (ADA). Data were obtained from electronic databases (CDC sector) and through surveys (hospital sector), and were estimated for the two sectors and for the country as a whole. Test costs were estimated by staff at China CDC, and using published literature.
RESULTS: In 2012, the China CDC and hospital sectors performed a total of 44 million TB diagnostic tests at an overall value of US$294 million. Tests used by the CDC sector were smear microscopy, solid and liquid culture and DST, while the hospital sector also used IGRAs, NAATs, ADA and serology. The hospital sector accounted for 76% of the overall test volume and 94% of the market value.
CONCLUSION: China has a very large TB diagnostic market that encompasses a wide range of diagnostic tests, with the majority being performed in Chinese hospitals.
Keywords: costs; diagnosis; tests; volumes
Document Type: Research Article
Affiliations: 1: National Tuberculosis Reference Laboratory of Chinese Center for Disease Control and Prevention, National Center for TB Control and Prevention, Chinese Center for Disease Control and Prevention, No 155, Chang Bai Road, Changping District, Beijing 102206, P R China. [email protected] 2: National Tuberculosis Reference Laboratory, China Center for Disease Control and Prevention, Beijing, China 3: Tuberculosis surveillance and statistics department, China Center for tuberculosis control and prevention, China Center for Disease Control and Prevention, Beijing, China 4: Bill and Melinda Gates Foundation China, Beijing, China 5: PATH, Beijing Office, Beijing, China 6: UNITAID, Geneva, Switzerland 7: FIND, Geneva, Switzerland 8: Independent consultant, currently consulting for FIND and UNITAID, Philadelphia, Pennsylvania, USA 9: Zurich, Switzerland 10: McGill International TB Centre, Montreal, Canada 11: FIND, Geneva, Switzerland; McGill International TB Centre, Montreal, Canada; Department of Epidemiology and Biostatistics, McGill University, Montreal, Quebec, Canada 12: McGill International TB Centre, Montreal, Canada; Department of Epidemiology and Biostatistics, McGill University, Montreal, Quebec, Canada 13: KNCV Tuberculosis Foundation, PO Box 146, 2501 CC The Hague, The Netherlands. [email protected]
Publication date: 01 March 2016
The International Journal of Tuberculosis and Lung Disease (IJTLD) is for clinical research and epidemiological studies on lung health, including articles on TB, TB-HIV and respiratory diseases such as COVID-19, asthma, COPD, child lung health and the hazards of tobacco and air pollution. Individuals and institutes can subscribe to the IJTLD online or in print – simply email us at [email protected] for details.
The IJTLD is dedicated to understanding lung disease and to the dissemination of knowledge leading to better lung health. To allow us to share scientific research as rapidly as possible, the IJTLD is fast-tracking the publication of certain articles as preprints prior to their publication. Read fast-track articles.
- Editorial Board
- Information for Authors
- Subscribe to this Title
- International Journal of Tuberculosis and Lung Disease
- Public Health Action
- Ingenta Connect is not responsible for the content or availability of external websites
Receive new issue alert- Access Key
- Free content
- Partial Free content
- New content
- Open access content
- Partial Open access content
- Subscribed content
- Partial Subscribed content
- Free trial content